Evidence map›Paper›PMID 28738906›Full record

ArticleGenome medicine2017

Next-generation sequencing to monitor the spread of antimicrobial resistance.

Michael Otto

Abstract readComment
In one paragraph

Article in Genome medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Review
  2. Observational
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. The Continuing Threat of Methicillin-ResistantAntibiotics (Basel, Switzerland) · 2019
    Review
  12. Review
  13. Methicillin-resistantAIMS microbiology · 2019
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author.

Michael OttoPathogen Molecular Genetics Section, Laboratory of Bacteriology, National Institute of Allergy and Infectious Diseases, U.S. National Institutes of Health, Bethesda, MD, 20814, USA. motto@niaid.nih.gov.ORCID 0000-0002-2222-4115

Funding

Staphylococcal pathogenesisZIAAI000904 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI OTTO, MICHAEL · 2009 to 2025
$22.6M
Intramural NIH HHS ZIA AI000904
6 · The paper itself

Abstract

Next-generation sequencing is increasingly being used to monitor current and historic events related to the emergence and spread of antimicrobial resistance. In a recent publication, researchers analyzed the rise of methicillin-resistant Staphylococcus aureus in the 1960s, emphasizing that adaptations conferring antibiotic resistance might pre-date the introduction of novel antibiotic derivatives. Other researchers have evaluated the role of transmission within a healthcare network, using the example of extended-spectrum beta-lactamase-resistant Escherichia coli.Please see related Genome Biology Research article: www.dx.doi.org/10.1186/s13059-017-1252-9 and Genome Medicine Research article: www.dx.doi.org/10.1186/s13073-017-0457-6.

Indexed as

Anti-Bacterial Agentsbeta-LactamasesDrug Resistance, BacterialEscherichia coliHigh-Throughput Nucleotide SequencingHumansMethicillin ResistanceMethicillin-Resistant Staphylococcus aureusStaphylococcal InfectionsStaphylococcus aureusAnti-Bacterial Agentsbeta-LactamasesAntibiotic resistanceESBLEscherichia coliMRSANext-generation sequencingStaphylococcus aureus

Identifiers

PMID28738906
PMCPMC5525366

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.